Moberg Pharma: U.S. patent extends IP runway to end of 2041 - Redeye

Moberg Pharma: U.S. patent extends IP runway to end of 2041 - Redeye

This morning, Moberg Pharma announced that the USPTO has granted a patent covering an improved dosing regimen for MOB-015, with projected expiry in December 2041. The U.S. is the first market to grant a patent on the improved dosing, and corresponding applications are under examination in other markets. While the news has no near-term financial impact, it adds roughly a decade of potential protection beyond the existing patents expiring in 2032, and it meaningfully strengthens the long-term value of the U.S. opportunity, where Moberg retains full rights.

Länk till analysen i sin helhet: https://www.redeye.se/research/1190424/moberg-pharma-moberg-pharma-u-s-patent-extends-ip-runway-to-end-of-2041?utm_source=finwire&utm_medium=RSS